GLP1R and chronic kidney disease: More recently there is evidence for the use nsMRA and GLP-1 RA which can also delay progression of CKD, which has resulted in a concept of pillars of cardio-renal pharmacotherapy for CKD and thereby the potential for addressing residual cardio-renal risk with a multipronged approach with medications that act on distinct pathways to confer organ protection.9